Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Perceptive Advisors
Deal Size : $21.4 million
Deal Type : Public Offering
Opus Genetics Prices Public Offering & Private Placement Over $20M
Details : Opus intends to use the net proceeds to fund clinical development of its lead gene therapy programs, OPGx-LCA5 for the treatment of leber congenital amaurosis.
Product Name : OPGx-LCA5
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
March 21, 2025
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Perceptive Advisors
Deal Size : $21.4 million
Deal Type : Public Offering
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Opus Presents Phentolamine Ophthalmic Data at World Cornea Congress IX
Details : Nyxol (phentolamine ophthalmic solution 0.75%) is being evaluated for the treatment in patients with dim light disturbances and decreased mesopic vision.
Product Name : Nyxol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 21, 2025
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Opus Gets FDA Fast Track for Phentolamine Ophthalmic
Details : Nyxol (phentolamine mesylate) an alpha1/2 adrenergic receptor inhibitor, is being investigated for decreased visual acuity under low light conditions following keratorefractive surgery.
Product Name : Nyxol
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 26, 2025
Lead Product(s) : Phentolamine Mesylate
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : AAV8.hLCA5
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Opus Genetics Announces Updates on OPGx-LCA5 Clinical Program
Details : OPGx-LCA5 is an investigational gene therapy, which is currently being evaluated for the treatment of patients with leber congenital amaurosis.
Product Name : OPGx-LCA5
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
February 18, 2025
Lead Product(s) : AAV8.hLCA5
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : APX3330
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Opus Genetics Receives FDA Agreement for Phase 3 Trial of APX3330 in Diabetic Retinopathy
Details : APX3330 is an oral small-molecule inhibitor of Ref-1, which is currently being evaluated for the treatment of patients with non-proliferative diabetic retinopathy.
Product Name : Undisclosed
Product Type : Small molecule
Upfront Cash : Not Applicable
December 19, 2024
Lead Product(s) : APX3330
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : APX3330
Therapeutic Area : Ophthalmology
Study Phase : Phase II
Sponsor : Ocuphire Pharma
Deal Size : Undisclosed
Deal Type : Merger
Ocuphire Pharma Announces Acquisition of Opus Genetics
Details : The acquisition creates a leading, clinical-stage company focused on developing gene therapies, including APX3330, an oral small-molecule inhibitor of Ref-1 for non-proliferative diabetic retinopathy.
Product Name : APX3330
Product Type : Small molecule
Upfront Cash : Undisclosed
October 22, 2024
Lead Product(s) : APX3330
Therapeutic Area : Ophthalmology
Highest Development Status : Phase II
Sponsor : Ocuphire Pharma
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Opus Genetics Receives FDA Rare Pediatric Disease Designation for OPGx-LCA5
Details : OPGx-LCA5 is an AAV8 vector designed to precisely deliver a functional LCA5 gene to the outer retina in patients with Leber congenital amaurosis resulting from biallelic mutations in the LCA5 gene.
Product Name : OPGx-LCA5
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
August 20, 2024
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : OPGx-RHO
Therapeutic Area : Genetic Disease
Study Phase : Preclinical
Sponsor : Foundation Fighting Blindness
Deal Size : $1.7 million
Deal Type : Funding
Opus Genetics Announces $1.7 Million in Funding for Preclinical Programs
Details : The proceeds will be used to conduct a preclinical safety study for OPGx-RHO, a gene therapy that targets autosomal dominant retinitis pigmentosa caused by RHO mutations (RHO-adRP).
Product Name : OPGx-RHO
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
June 13, 2024
Lead Product(s) : OPGx-RHO
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Sponsor : Foundation Fighting Blindness
Deal Size : $1.7 million
Deal Type : Funding
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Opus Genetics Completes Dosing in Phase 1/2 Trial of Gene Therapy OPGx-LCA5
Details : OPGx-LCA5 uses an AAV8 vector to deliver a functional LCA5 gene to the retina for patients with Leber congenital amaurosis from LCA5 mutations.
Product Name : OPGx-LCA5
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
March 26, 2024
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : OPGx-LCA5, an adeno-associated virus 8 (AAV8) vector designed to precisely deliver a functional LCA5 gene to the outer retina in patients with Leber congenital amaurosis (LCA) resulting from biallelic mutations in the LCA5 gene (LCA5).
Product Name : OPGx-LCA5
Product Type : Cell and Gene therapy
Upfront Cash : Not Applicable
September 07, 2023
Lead Product(s) : OPGx-LCA5
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Phase I/ Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable